Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.

doi:10.1158/2159-8290.CD-17-0261

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.

Cancer discovery - 1 Sept 2017

Goodall Jane, Mateo Joaquin, Yuan Wei, Mossop Helen, Porta Nuria, Miranda Susana, Perez-Lopez Raquel, Dolling David, Robinson Dan R, Sandhu Shahneen, Fowler Gemma, Ebbs Berni, Flohr Penny, Seed George, Rodrigues Daniel Nava, Boysen Gunther, Bertan Claudia, Atkin Mark, Clarke Matthew, Crespo Mateus, Figueiredo Ines, Riisnaes Ruth, Sumanasuriya Semini, Rescigno Pasquale, Zafeiriou Zafeiris, Sharp Adam, Tunariu Nina, Bianchini Diletta, Gillman Alexa, Lord Christopher J, Hall Emma, Chinnaiyan Arul M, Carreira Suzanne, de Bono Johann S

Abstract excerpt

Biomarkers for more precise patient care are needed in metastatic prostate cancer. We have reported a phase II trial (TOPARP-A) of the PARP inhibitor olaparib in metastatic prostate cancer, demonstrating antitumor activity associating with homologous recombination DNA repair defects. We now report targeted and whole-exome sequencing of serial circulating cell-free DNA (cfDNA) samples collected during this trial....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell-Free Nucleic Acids

Share to Exome Sequencing

Share to Phthalazines

Share to Piperazines

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Prognosis

Share to Prostatic Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 28450425
DOI: 10.1158/2159-8290.CD-17-0261
PMCID: PMC6143169

Genes

BRCA2
PALB2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.PMID 28450425Read ↗

Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic.Semantic proximity Read ↗

Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesisSemantic proximity Read ↗

Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms.Semantic proximity Read ↗

Clinical implications of genomic alterations in metastatic prostate cancer.Semantic proximity Read ↗

Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesisSemantic proximity Read ↗

BRCAness and prostate cancer: diagnostic and therapeutic considerations.Semantic proximity Read ↗

Clinical determinants for successful circulating tumor DNA analysis in prostate cancerSemantic proximity Read ↗

Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.Semantic proximity Read ↗

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.Semantic proximity Read ↗

Integrative genomic and epigenomic profiling in plasma and urinary cell-free DNA improves early risk stratification of newly diagnosed prostate cancerSemantic proximity Read ↗

Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.Semantic proximity Read ↗

Cell-Free DNA Detection of Tumor Mutations in Heterogeneous, Localized Prostate Cancer Via Targeted, Multiregion Sequencing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.